ZTX’s Post

☑️ Cognito Therapeutics, Inc. Spectris AD device slows cognitive decline in Alzheimer’s by delivering flashing lights and sounds to stimulate gamma waves in the brain. ☑️ Roche acquires Point of Care technology from LumiraDx, introducing a multi-assay point-of-care platform into its operations. ☑️ Fujirebio Diagnostics, Inc. introduces the Lumipulse G GFAP assay in the US, set to release in Japan, Europe, and other regions by September 2024. ☑️ C2N Diagnostics PrecivityAD2 blood test shows high accuracy in identifying Alzheimer’s, suitable for screening in primary and secondary care settings ☑️ Implantica reveals positive results for its RefluxStop implant, improving or resolving symptoms in 90% of enrolled patients. #InsightswithSmarteeva #Medtech #complaintmanagement #Pharma #Smarteeva #biotech #medtechtrends #medtechindustry #medicaltechnology #technology #health #medicaldevicediagnostics #ai #mdr #recalls #complaints #mir #fda #cvr

Nanorobots: The revolution in drug delivery - https://lnkd.in/eRbh6pWG -The field of medicine is undergoing a revolutionary transformation with the development of nanorobot drug delivery systems. These tiny machines, designed at the nanoscale, promise to change the way we treat diseases, offering unprecedented precision and effectiveness. What Are Nanorobots? Nanorobots are microscopic devices, typically less than 100 nanometers in

Nanorobots: The revolution in drug delivery - https://lnkd.in/eBTe_J43 -The field of medicine is undergoing a revolutionary transformation with the development of nanorobot drug delivery systems. These tiny machines, designed at the nanoscale, promise to change the way we treat diseases, offering unprecedented precision and effectiveness. What Are Nanorobots? Nanorobots are microscopic devices, typically less than 100 nanometers in

An Israeli company, TechsoMed – headed by Technion alumni CEO Yossi Abu and Chief Strategy Officer Eran Naveh – has just received FDA clearance for its groundbreaking liver tumor software. The software is used during ablation therapy – a minimally invasive treatment that uses extreme temperatures to kill tumors – and is designed to predict the tissue response to the therapy. This innovation promises to revolutionize the way we diagnose and treat liver tumors. Learn more about this game-changing development and how Technion - Israel Institute of Technology graduates continue to change the world. https://lnkd.in/gSk7-Adi #Technion #TechnionAlumni #TechnionImpact

What is #theranostic? 🤔 When we talk about the theranostic approach of PHIRE's technology we are referring to the combination of therapeutic and diagnostic capabilities that it offers. 💡The primary goal of theranostics is to integrate both therapeutic and diagnostic functions to create a more personalised and targeted approach to medical treatment. Theranostic nanoparticles are designed to carry both therapeutic payloads and diagnostic components. This combination allows for simultaneous monitoring of the disease and delivery of therapeutic interventions. 🏥 Theranostic can enhance the delivery of therapeutics to specific target sites, reduce side effects, and provide valuable information about the disease state. More about PHIRE project 👉 https://lnkd.in/ejk-3zuB Ospedale San Raffaele | Alma Mater Studiorum – Università di Bologna | FUJIFILM Sonosite, Inc. | META Group | Ascend Technologies Ltd. | European Innovation Council and SMEs Executive Agency (EISMEA) #nanomedicine #bladdercancer #custommedicine #OpenScience #nanorods #bladdercancer #earlydetection #photoacoustic

Important Abstract highlighting the thromboresistant CLAAS Design

𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐈𝐦𝐚𝐠𝐢𝐧𝐠 𝐄𝐪𝐮𝐢𝐩𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 📊 | 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://lnkd.in/dVZtpSw9 The Oncology Imaging Equipment Market is at the forefront of precision diagnostics, projected to experience robust growth as the demand for advanced cancer detection and monitoring technologies intensifies globally. This market, valued at $3.8 billion in 2023, is anticipated to reach $7.6 billion by 2032, reflecting a CAGR of 8.1%. Increasing cancer prevalence, ongoing technological advancements in imaging, and a strong push for early detection and targeted treatment options are key growth drivers for this market. Our Market Research Report delivers both quantitative and qualitative analysis of the Oncology Imaging Equipment Market, exploring the landscape of leading manufacturers, regional trends, equipment types, and clinical applications. The report also includes detailed company profiles, product samples, and 2024 market share estimates to provide a complete competitive perspective for businesses and stakeholders. 𝗕𝘆 𝗧𝘆𝗽𝗲: PET Scanners, CT Scanners, MRI Scanners, Ultrasound, X-Ray, SPECT 𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Diagnosis, Monitoring, Treatment Planning, Research 𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa 𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Siemens Healthineers, GE HealthCare, Philips, Canon Medical Systems Europe, Hitachi Aloka Medical America is now Hitachi Healthcare Americas, SHIMADZU CORPORATION, Samsung Medison, Hologic, Inc., Bruker, Carestream, Analogic, Esaote, ViewRay, Inc., Medtronic, Brainlab, Koning Health, United Imaging Healthcare, Curium Pharma, C-RAD AB, RaySearch Laboratories, Accuray, Zetta Medical Technologies, LLC, Mobius Imaging, now part of Stryker, Neusoft Medical, Thermo Fisher Scientific, Mindray Animal Medical, NordicNeuroLab, Spacelabs Healthcare, SPECTRASCIENCE INC, Optos, Arterys (Acquired by Tempus Labs) #oncologyimaging #cancerdiagnostics #medicaldevices #precisionmedicine #imagingtechnology #radiology #healthcareinnovation #cancertreatment #PETscan #CTscan #MRI #diagnosticimaging #earlycancerdetection #clinicalimaging #healthcaregrowth #globalmarket #marketresearch #medicalequipment #advancedimaging #cancercare

☑️ FDA greenlights Inspire Medical Systems’s neurostimulator therapy for obstructive sleep apnea, planning a soft launch of the Inspire V therapy system in the US later this year with a full launch in 2025. ☑️ Eyedaptic launches EYE6 with Ivy wearable vision aid, designed to enhance vision for individuals with AMD and other retinal disorders. ☑️ Rejuvenate Biomed and SAS partner to harness AI for age-related diseases, creating a tool to simplify drug development and repurpose drugs. ☑️ Microbot Medical and @Emory University to advance the Liberty endovascular robotic system by integrating it with an imaging system. ☑️ io9, Inc.’s AI cancer biomarker test, DeepHRD, outperforms NGS in a new study, showing superior performance compared to FDA-approved HRD diagnostics. #InsightswithSmarteeva #Medtech #complaintmanagement #Pharma #Smarteeva #biotech #medtechtrends #medtechindustry #medicaltechnology #technology #health #medicaldevicediagnostics #ai #mdr #recalls #complaints #mir #fda #cvr

🩺 Latest in MedTech: Diagnostics 🩺 ▶ Abbott has secured a #CE mark approval in Europe for its long-term insertable cardiac monitor, designed to help monitor a patient’s heart rhythms remotely for up to six years. The Bluetooth-equipped Assert-IQ is designed to record irregular heartbeats—including hard-to-catch cases of atrial fibrillation and alert clinicians to the data necessary for choosing the optimal course of treatment. ▶ The protein sequencing company Alamar Biosciences, Inc. has collected $128 million in venture capital funding to boost the commercial roll out of its research hardware unveiled in the past year. The series C round which includes an initial closing of $100 million, with the remaining $28 million expected to come in the next month, was led by Sands Capital, and included backing from additional unnamed investors. ▶ GE HealthCare said its artificial intelligence programs were able to help predict cancer patients’ responses to immunotherapies by finding patterns within routinely collected clinical data. According to the company, the algorithms were able to deliver 70% to 80% accuracy in forecasting efficacy outcomes and the likelihood of unwanted side effects, across a range of different cancer types. #ai #clinicaldata #Diagnostics #algorithms #cardiology #oncology #vcfunding #satigo #diagnosticsnews #medtech

JOGO Health Announces Collaboration With Mayo Clinic to Study Tremors Using AI Powered Digital Therapeutics: 📲The partnership combines both organizations' expertise in medical analysis and device development, focusing on Parkinson's tremors, functional tremors (FT), and essential tremors (ET) 📲 The study aims to pressure test the effectiveness of AI-driven digital therapeutics in treating tremors that significantly impact the quality of life for individuals with Parkinson's, FT, and ET. 📲 Particular focus will be given to FT where current treatments are limited, often requiring patients to take substantial time off work or school 📲 JOGO Health and Mayo Clinic aspire to expand the range of viable treatment options, making specialized therapy more accessible and less disruptive to patients' daily lives 📲 JOGO Health's proprietary non-invasive digital therapeutic device, JOGO-Gx, integrates Al and wearable technology, having shown early success in treating Parkinson's Disease (Mayo Clinic have a financial interest in the tech) 📲 The upcoming study, planned start in September 2024, will run for one year, assessing the efficacy of this pioneering approach and guide further device development 📲 JOGO is a Digital Therapeutics company that uses wearable sensors and an AI-driven app to treat chronic pain, Parkinson's tremors and other movement disorders associated with neurological conditions via telemedicine 👇Link to relevant articles below in comments #digitalhealth #ai #dtx